Psyence Biomedical LTD. (PBMWW) — 6-K Filings

All 6-K filings from Psyence Biomedical LTD.. Browse 38 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (38)

6-K Filing — Nov 21, 2025
Psyence Biomedical Ltd. Files Interim Financials — Nov 20, 2025 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on November 20, 2025, to report its unaudited interim consolidated financial statements for the three and six months en
Psyence Biomedical Appoints CFO to Board, Amends Stock Purchase Agreement — Nov 10, 2025 Risk: low
Psyence Biomedical Ltd. announced the appointment of Warwick Corden-Lloyd, the company's Chief Financial Officer, to its Board of Directors, effective October 3
Psyence Biomedical Ltd. Names New Head of Clinical Development — Oct 9, 2025 Risk: low
Psyence Biomedical Ltd. announced on October 9, 2025, that Dr. Neil Maresky has transitioned from CEO and Director to Global Head of Clinical Development. In hi
Psyence Biomedical Buys PsyLabs Shares for $3.5M — Sep 5, 2025 Risk: medium
On August 15, 2025, Psyence Biomedical Ltd. entered into a subscription agreement with Psyence Labs Ltd. (PsyLabs). Under this agreement, PsyLabs will issue 1,7
Psyence Biomedical Ltd. Files August 2025 Report (6-K) — Aug 28, 2025 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on August 28, 2025, reporting for the month of August 2025. The filing includes a press release as Exhibit 99.1. The co
Psyence Biomedical Ltd. Enters LOI with Southern Star Research — Jun 11, 2025 Risk: low
On April 2, 2025, Psyence Biomedical Ltd. announced a binding letter of intent (LOI) with Southern Star Research Pty Ltd, an Australian contract research organi
Psyence Biomedical Ltd. Files 6-K Report — May 20, 2025 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on May 20, 2025, reporting its status as a foreign private issuer. The company, located at 121 Richmond Street West, Pe
Psyence Biomedical Ltd. Files Form 6-K — May 6, 2025 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on May 6, 2025, reporting information for the month of May 2025. The filing includes a press release as Exhibit 99.1. T
Psyence Biomedical Ltd. Approves Up to 50-for-1 Reverse Stock Split — Apr 23, 2025 Risk: medium
Psyence Biomedical Ltd. held a Special Meeting of Shareholders on April 16, 2025, to approve a share consolidation proposal. The board of directors is authorize
Psyence Biomedical Ltd. to Conduct Phase IIb Trial for Alcohol Use Disorder — Apr 11, 2025 Risk: medium
On April 2, 2025, Psyence Biomedical Ltd. announced a binding letter of intent (LOI) with Southern Star Research Pty Ltd for Psyence Australia Pty Ltd to conduc
Psyence Biomedical Ltd. Files 6-K, Incorporates Corporate Update — Apr 1, 2025 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on April 1, 2025, to incorporate by reference a Corporate Update (Exhibit 99.1) into its existing Registration Statemen
Psyence Biomedical Ltd. Calls Special Shareholder Meeting — Mar 31, 2025 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on March 31, 2025, announcing a Special Meeting of Shareholders scheduled for April 16, 2025. The filing includes the n
Psyence Biomedical Ltd. Files 6-K with Financial Instrument Details — Jan 23, 2025 Risk: medium
Psyence Biomedical Ltd. filed a 6-K report for the period ending September 30, 2024. The filing includes details on various financial instruments such as warran
Psyence Biomedical Files 6-K Detailing Securities Agreements — Dec 31, 2024 Risk: medium
Psyence Biomedical Ltd. filed a Form 6-K on December 31, 2024, reporting on events for the month of December 2024. The filing includes several exhibits related
Psyence Biomedical Ltd. Files 6-K Report — Dec 23, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on December 23, 2024, reporting for the month of December 2024. The filing includes a press release as Exhibit 99.1. Dr
Psyence Biomedical Ltd. inks deals with Optimi Health Corp. — Dec 19, 2024 Risk: medium
On December 5, 2024, Psyence Biomedical Ltd. entered into three definitive agreements with Optimi Health Corp. These agreements include an Intellectual Property
Psyence Biomedical Ltd. Files 6-K Report — Dec 18, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on December 18, 2024, reporting information for the month of December 2024. The filing includes a press release as Exhi
Psyence Biomedical Ltd. Files 6-K on Debt-for-Equity Swap — Dec 4, 2024 Risk: medium
Psyence Biomedical Ltd. filed a Form 6-K on December 4, 2024, reporting on a Debt-for-Equity Swap Agreement effective September 30, 2024, and a First Addendum t
Psyence Biomedical Ltd. Files Form 6-K — Dec 3, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on December 3, 2024, to report a press release. The filing includes the signature of Dr. Neil Maresky, Chief Executive
Psyence Biomedical Ltd. Files 6-K with Key Agreements and Nasdaq News — Nov 22, 2024 Risk: medium
Psyence Biomedical Ltd. filed a Form 6-K on November 22, 2024, reporting on several key events. These include a Termination Agreement dated November 21, 2024, a
Psyence Biomedical Ltd. Files 6-K Report — Nov 12, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on November 12, 2024, reporting for the month of November 2024. The filing includes a press release as Exhibit 99.1. Th
Psyence Biomedical Ltd. Files 6-K Report — Nov 1, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on November 1, 2024, reporting for the month of November 2024. The filing includes a press release as Exhibit 99.1. Dr.
Psyence Biomedical Schedules Shareholder Meeting, Files Financials — Oct 23, 2024 Risk: low
Psyence Biomedical Ltd. has filed a Form 6-K, announcing its Annual General and Special Meeting of Shareholders scheduled for November 12, 2024. The filing also
Psyence Biomedical Swaps Debt for Equity — Oct 8, 2024 Risk: medium
Psyence Biomedical Ltd. announced on September 30, 2024, that it entered into debt-for-equity swap agreements. This move aims to restructure the company's debt
Psyence Biomedical Ltd. Enters Share Purchase Agreement — Sep 20, 2024 Risk: medium
On September 17, 2024, Psyence Biomedical Ltd. entered into a Share Purchase and Sale Agreement. The filing does not specify the other party involved or the fin
Psyence Biomedical Ltd. Issues Press Release — Sep 13, 2024 Risk: low
On September 13, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical prep
Psyence Biomedical Ltd. Enters New License Agreement — Sep 5, 2024 Risk: medium
On September 3, 2024, Psyence Biomedical Ltd. entered into a license agreement concerning alcohol and substance use disorders. The filing does not specify the o
Psyence Biomedical Ltd. Files Investor Presentation 6-K — Aug 30, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on August 30, 2024, to report an investor presentation. This presentation is intended for use by management in discussi
Psyence Biomedical Ltd. Enters Securities Agreement Addendum — Aug 20, 2024 Risk: low
On August 15, 2024, Psyence Biomedical Ltd. entered into a first addendum to a Securities Purchase Agreement. The filing is a Form 6-K, reporting for the month
Psyence Biomedical Ltd. Enters Stock Purchase Agreement — Jul 31, 2024 Risk: medium
On July 25, 2024, Psyence Biomedical Ltd. entered into a Common Stock Purchase Agreement. The filing does not specify the other party or the financial terms of
Psyence Biomedical Ltd. Files 6-K on Agreement Changes — Jul 24, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on July 24, 2024, reporting on the modification and termination of material agreements involving Psyence Group Inc. (PG
Psyence Biomedical Ltd. Files 6-K Update — Jul 23, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on July 23, 2024, providing an update related to its initial business combination that closed on January 15, 2024. The
Psyence Biomedical Faces Nasdaq Delisting Risk — Jul 5, 2024 Risk: medium
On June 27, 2024, Psyence Biomedical Ltd. received a notification letter from Nasdaq regarding its failure to meet the minimum bid price requirement, with a com
Psyence Biomedical Ltd. Files 6-K Update — Jun 20, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on June 20, 2024, providing an update as a foreign private issuer. The filing references a previous disclosure from Jan
Psyence Biomedical Ltd. Files 6-K Update — Jun 6, 2024 Risk: low
Psyence Biomedical Ltd. filed a Form 6-K on June 6, 2024, providing an update on its business. The filing references a previous disclosure from January 15, 2024
Psyence Biomedical Ltd. Files Form 6-K — Mar 15, 2024 Risk: low
On March 15, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical preparat
Psyence Biomedical Ltd. Files Form 6-K for March 2024 — Mar 12, 2024 Risk: low
On March 6, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical preparati

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX